Oxford Gene Technology (OGT), Oxford, UK, has updated its myPanel customizable SureSeq NGS panels to include accurate detection capabilities for translocations and difficult-to-sequence partial tandem duplications (PTDs).
The latest update is beneficial to researchers investigating myeloid disorders such chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML), and is now enabled with BCR-ABL fusion gene and KMT2A-PTD detection.
OGT already offers researchers the rapid and reliable detection of a complete set of genetic aberrations, including single nucleotide variations (SNVs), insertions/deletions (indels), internal tandem duplications (ITD), copy number variations (CNVs), and loss of heterozygosity (LOH)—even at low-frequencies.
For more information, visit Oxford Gene Technology.
